{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifaxalc5khy3txcd2q7h3l5kcbea3far2vuqgwf6joeaikqsyt6oa",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mna7t2qilyo2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibmgt76hgixp7iq2le65iejjc5o6s5yv2akkkp2lbn5zgkc4nycdu"
    },
    "mimeType": "image/jpeg",
    "size": 72729
  },
  "path": "/2026/06/01/servier-edgewise-therapeutics-muscular-dystrophy-drug-sevasemten/?utm_campaign=rss",
  "publishedAt": "2026-06-01T12:31:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "drug development",
    "Pharmaceuticals",
    "rare disease",
    "STAT+"
  ],
  "textContent": "The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.",
  "title": "STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug",
  "updatedAt": "2026-06-01T12:02:14.000Z"
}